Equities research analysts expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to report earnings of ($0.56) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings, with estimates ranging from ($0.63) to ($0.52). Spring Bank Pharmaceuticals posted earnings of ($0.29) per share during the same quarter last year, which indicates a negative year over year growth rate of 93.1%. The firm is expected to report its next earnings report on Wednesday, August 7th.
On average, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($2.18) per share for the current year, with EPS estimates ranging from ($3.19) to ($1.83). For the next year, analysts expect that the company will post earnings of ($2.99) per share, with EPS estimates ranging from ($4.07) to ($2.30). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Monday, April 29th. The company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.20.
A number of equities research analysts recently weighed in on SBPH shares. Cantor Fitzgerald set a $9.00 price target on shares of Evofem Biosciences and gave the stock a “buy” rating in a research note on Friday, April 12th. Dawson James reaffirmed a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, May 13th. Chardan Capital set a $10.00 target price on shares of Arcimoto and gave the company a “buy” rating in a research note on Friday, April 12th. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Finally, ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $19.30.
In other news, insider Martin J. Driscoll bought 10,000 shares of the stock in a transaction on Tuesday, April 30th. The stock was purchased at an average price of $7.34 per share, with a total value of $73,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Scott Andrew Smith purchased 12,000 shares of Spring Bank Pharmaceuticals stock in a transaction dated Friday, June 28th. The stock was bought at an average price of $4.09 per share, with a total value of $49,080.00. The disclosure for this purchase can be found here. Insiders acquired 42,000 shares of company stock valued at $242,930 in the last ninety days. Insiders own 15.60% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its holdings in shares of Spring Bank Pharmaceuticals by 0.9% in the fourth quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock valued at $1,785,000 after buying an additional 1,507 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Spring Bank Pharmaceuticals by 5.9% in the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock valued at $454,000 after buying an additional 2,430 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in shares of Spring Bank Pharmaceuticals by 1,395.4% in the first quarter. BNP Paribas Arbitrage SA now owns 2,946 shares of the company’s stock valued at $31,000 after buying an additional 2,749 shares during the period. Rhumbline Advisers boosted its holdings in shares of Spring Bank Pharmaceuticals by 65.3% in the fourth quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock valued at $174,000 after buying an additional 6,623 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Spring Bank Pharmaceuticals by 8.7% during the fourth quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock worth $1,214,000 after purchasing an additional 9,398 shares during the last quarter. Institutional investors own 42.93% of the company’s stock.
Shares of SBPH traded up $0.06 on Friday, reaching $5.12. 38,500 shares of the company’s stock were exchanged, compared to its average volume of 144,839. The company has a debt-to-equity ratio of 0.06, a current ratio of 12.11 and a quick ratio of 12.11. The stock has a market cap of $84.19 million, a PE ratio of -2.74 and a beta of 0.37. The stock’s 50 day simple moving average is $4.68. Spring Bank Pharmaceuticals has a 12 month low of $3.58 and a 12 month high of $15.00.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.